Enhanced antibody responses to a detoxified lipopolysaccharide-group B meningococcal outer membrane protein vaccine are due to synergistic engagement of Toll-like receptors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Innate Immunity

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1177/1753425909346973PMID 19822632PMCID PMC3810117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunostimulatory activity of haptenated proteins

  2009cited by this paper
• Intranasal administration of a detoxified endotoxin vaccine protects mice against heterologous Gram-negative bacterial pneumonia

  2008cited by this paper
• T-cell quality in memory and protection: implications for vaccine design

  2008cited by this paper
• TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells.

  2008cited by this paper
• Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells.

  2008cited by this paper
• Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation.

  2007cited by this paper
• B cell–intrinsic TLR signals amplify but are not required for humoral immunity

  2007cited by this paper
• Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.

  2005influential reference
• Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells

  2005cited by this paper
• In Vivo Humoral Immune Responses to Isolated Pneumococcal Polysaccharides Are Dependent on the Presence of Associated TLR Ligands1

  2005cited by this paper
• Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.

  2004cited by this paper
• Haemophilus influenzae Type b-Outer Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal Immunogenicity1

  2004cited by this paper
• A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

  2003cited by this paper
• Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

  2003cited by this paper
• Recent advances in immunostimulatory CpG oligonucleotides.

  2003cited by this paper
• CpG DNA as a vaccine adjuvant

  2003cited by this paper
• CpG DNA as a vaccine adjuvant

  2003cited by this paper
• Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

  2001influential reference
• Resistance patterns among nosocomial pathogens: trends over the past few years.

  2001cited by this paper
• Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.

  2001cited by this paper
• The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

  2001cited by this paper
• Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

  2000cited by this paper
• CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

  2000cited by this paper
• Repeated Administration of Synthetic Oligodeoxynucleotides Expressing CpG Motifs Provides Long-Term Protection against Bacterial Infection

  1999cited by this paper
• Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.

  1999cited by this paper
• Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

  1998influential reference
• A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

  1996influential reference
• Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

  1994influential reference
• Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection.

  1992cited by this paper
• A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis

  1991cited by this paper
• A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.

  1991cited by this paper
• Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

  1991cited by this paper
• Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

  1991cited by this paper
• Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.

  1988cited by this paper
• Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

  1982cited by this paper
• Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.

  1975cited by this paper
• Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

  1973cited by this paper
• THE BIOSYNTHESIS OF CELL WALL LIPOPOLYSACCHARIDE IN ESCHERICHIA COLI. I. THE BIOCHEMICAL PROPERTIES OF A URIDINE DIPHOSPHATE GALACTOSE 4-EPIMERASELESS MUTANT.

  1965cited by this paper

• Integration of Innate Immune Signaling.

  2016cites this paper
• Integration of Innate Immune

  2016cites this paper
• Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza.

  2012cites this paper
• Improvement of Immunogenicity of Meningococcal Lipooligosaccharide by Coformulation with Lipidated Transferrin-Binding Protein B in Liposomes: Implications for Vaccine Development

  2012cites this paper
• Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants

  2012cites this paper
• Hepatitis C Virus Reveals a Novel Early Control in Acute Immune Response

  2011cites this paper
• Murine J774 macrophages recognize LPS/IFN-g, non-CpG DNA or two-CpG DNA-containing sequences as immunologically distinct.

  2010cites this paper
• Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins

  2010cites this paper
• Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

  2010cites this paper